莱美药业 reported revenue of ¥0.35B for the period ended 2026-06-30, -7.1% year on year. Net income was ¥-0.02B, a -6.5% net margin on a 51.9% gross margin. The largest revenue line is 特色专科类 at 33% of the total. Free cash flow for the period was ¥0.05B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.35B | -7.1% |
| Gross profit | ¥0.18B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | — |
| Gross margin | 51.9% | Net margin -6.5% |
| Revenue Q/Q | -7.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 特色专科类 | ¥0.11B | 32.6% |
| 大输液类 | ¥0.09B | 26.4% |
| 医药流通类 | ¥0.09B | 26.1% |
| 抗感染类 | ¥0.03B | 8.1% |
| 服务收入 | ¥0.01B | 3.7% |
| 其他品种 | ¥0.01B | 2.2% |
| 其他(补充) | ¥0.00B | 0.8% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.17B | 48.1% |
| R&D | ¥0.02B | 5.1% |
| SG&A | ¥0.17B | 48.9% |
| Tax & other | ¥0.00B | 0.1% |
| Item | Amount |
|---|---|
| Total assets | ¥2.73B |
| Total liabilities | ¥0.98B |
| Shareholders' equity | ¥1.75B |
| Equity / assets | 64.0% |
| Operating cash flow | ¥0.06B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥0.05B |
| Cash conversion (OCF / net income) | -105% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术 ・ 华测检测 ・ 新宁物流 ・ 北陆药业 ・ 网宿科技 ・ 中元股份 ・ 硅宝科技 ・ ST银江
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies